CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity

BLA FilingPositive
AI Analysis

Summary

Candel Therapeutics is nearing a year-end BLA filing for its prostate cancer drug, which represents a $10–$16B market opportunity.

Importance:7/10
Sentiment:
0.60
BLA filingprostate cancerregulatory milestonemarket opportunity
Related Companies

Read the original article

Published by yahoo_finance on August 12, 2026 7:08 PM

Read Original